Historical Valuation
GT Biopharma Inc (GTBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.15. The fair price of GT Biopharma Inc (GTBP) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.63
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
GT Biopharma Inc (GTBP) has a current Price-to-Book (P/B) ratio of 1.65. Compared to its 3-year average P/B ratio of 0.56 , the current P/B ratio is approximately 194.33% higher. Relative to its 5-year average P/B ratio of 2.42, the current P/B ratio is about -31.75% higher. GT Biopharma Inc (GTBP) has a Forward Free Cash Flow (FCF) yield of approximately -130.72%. Compared to its 3-year average FCF yield of -177.75%, the current FCF yield is approximately -26.46% lower. Relative to its 5-year average FCF yield of -111.97% , the current FCF yield is about 16.75% lower.
P/B
Median3y
0.56
Median5y
2.42
FCF Yield
Median3y
-177.75
Median5y
-111.97
Competitors Valuation Multiple
AI Analysis for GTBP
The average P/S ratio for GTBP competitors is 0.04, providing a benchmark for relative valuation. GT Biopharma Inc Corp (GTBP.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for GTBP
1Y
3Y
5Y
Market capitalization of GTBP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of GTBP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is GTBP currently overvalued or undervalued?
GT Biopharma Inc (GTBP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.15. The fair price of GT Biopharma Inc (GTBP) is between to according to relative valuation methord.
What is GT Biopharma Inc (GTBP) fair value?
GTBP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of GT Biopharma Inc (GTBP) is between to according to relative valuation methord.
How does GTBP's valuation metrics compare to the industry average?
The average P/S ratio for GTBP's competitors is 0.04, providing a benchmark for relative valuation. GT Biopharma Inc Corp (GTBP) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for GT Biopharma Inc (GTBP) as of Jan 10 2026?
As of Jan 10 2026, GT Biopharma Inc (GTBP) has a P/B ratio of 1.65. This indicates that the market values GTBP at 1.65 times its book value.
What is the current FCF Yield for GT Biopharma Inc (GTBP) as of Jan 10 2026?
As of Jan 10 2026, GT Biopharma Inc (GTBP) has a FCF Yield of -130.72%. This means that for every dollar of GT Biopharma Inc’s market capitalization, the company generates -130.72 cents in free cash flow.
What is the current Forward P/E ratio for GT Biopharma Inc (GTBP) as of Jan 10 2026?
As of Jan 10 2026, GT Biopharma Inc (GTBP) has a Forward P/E ratio of -0.87. This means the market is willing to pay $-0.87 for every dollar of GT Biopharma Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for GT Biopharma Inc (GTBP) as of Jan 10 2026?
As of Jan 10 2026, GT Biopharma Inc (GTBP) has a Forward P/S ratio of 0.00. This means the market is valuing GTBP at $0.00 for every dollar of expected revenue over the next 12 months.